Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 03:47PM ET
1.54
Dollar change
+0.01
Percentage change
0.65
%
Index- P/E- EPS (ttm)-1.87 Insider Own3.02% Shs Outstand41.27M Perf Week-2.53%
Market Cap63.98M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float40.02M Perf Month-24.88%
Income-50.11M PEG- EPS next Q-0.27 Inst Own34.01% Short Float2.90% Perf Quarter-30.00%
Sales0.00M P/S- EPS this Y51.88% Inst Trans82.81% Short Ratio3.61 Perf Half Y-50.16%
Book/sh0.04 P/B40.32 EPS next Y44.10% ROA-170.31% Short Interest1.16M Perf Year-31.25%
Cash/sh0.82 P/C1.87 EPS next 5Y- ROE-474.63% 52W Range1.38 - 4.45 Perf YTD-44.40%
Dividend Est.- P/FCF- EPS past 5Y41.77% ROI-295.11% 52W High-65.39% Beta0.90
Dividend TTM- Quick Ratio1.77 Sales past 5Y0.00% Gross Margin- 52W Low11.19% ATR (14)0.11
Dividend Ex-Date- Current Ratio1.77 EPS Y/Y TTM50.73% Oper. Margin0.00% RSI (14)21.08 Volatility5.50% 6.89%
Employees23 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.33
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q69.30% Payout- Rel Volume0.27 Prev Close1.53
Sales Surprise- EPS Surprise-21.21% Sales Q/Q- EarningsNov 18 BMO Avg Volume321.61K Price1.54
SMA20-16.60% SMA50-22.28% SMA200-42.88% Trades Volume85,987 Change0.65%
Date Action Analyst Rating Change Price Target Change
Jul-01-20Initiated Oppenheimer Outperform
Jan-21-20Resumed ROTH Capital Buy $10
Sep-13-19Initiated ROTH Capital Buy
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Nov-21-24 08:00AM
Nov-19-24 01:39AM
Nov-18-24 07:05AM
Nov-14-24 08:05AM
Nov-12-24 08:05AM
04:05PM Loading…
Nov-11-24 04:05PM
Nov-07-24 06:40AM
Nov-01-24 05:00PM
Aug-26-24 06:40AM
Aug-23-24 05:00PM
Aug-13-24 06:40AM
Aug-08-24 05:15PM
04:05PM
Jul-23-24 06:40AM
Jul-22-24 06:40AM
06:40AM Loading…
Jun-27-24 06:40AM
May-29-24 06:40AM
May-15-24 08:18AM
03:43AM
03:02AM
May-14-24 10:53AM
06:40AM
May-08-24 06:40AM
May-07-24 06:40AM
Mar-28-24 10:33AM
Mar-27-24 10:09PM
10:53AM
06:40AM
Mar-20-24 06:40AM
Mar-14-24 08:52AM
06:40AM Loading…
Mar-04-24 06:40AM
Feb-07-24 06:40AM
Jan-30-24 06:40AM
Jan-25-24 06:40AM
Jan-22-24 06:40AM
Jan-16-24 06:40AM
Jan-12-24 06:44AM
Jan-11-24 06:40AM
Jan-08-24 08:37AM
06:40AM
06:30AM
Jan-03-24 08:30AM
Dec-19-23 08:30AM
Dec-12-23 08:30AM
Dec-05-23 08:30AM
Nov-04-23 12:36PM
Nov-02-23 07:30AM
Oct-25-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 08:00AM
Oct-02-23 06:35AM
Sep-18-23 08:40AM
Sep-11-23 06:30AM
Sep-05-23 08:21AM
Aug-14-23 08:40AM
Jun-30-23 09:40AM
Jun-28-23 08:30AM
Jun-12-23 08:30AM
May-04-23 09:22AM
08:40AM
Mar-09-23 08:40AM
Mar-08-23 04:05PM
Feb-28-23 08:30AM
Feb-15-23 08:30AM
Nov-30-22 08:30AM
Nov-21-22 08:30AM
Nov-16-22 08:30AM
Nov-03-22 08:30AM
Oct-25-22 04:30PM
Oct-21-22 08:30AM
Sep-22-22 08:30AM
Sep-13-22 08:30AM
Aug-30-22 02:55PM
Aug-05-22 08:30AM
Jul-21-22 04:15PM
Jun-20-22 09:22AM
May-10-22 08:30AM
Apr-26-22 08:00AM
Apr-12-22 08:30AM
Mar-23-22 06:35PM
Mar-21-22 08:30AM
Mar-10-22 04:05PM
Feb-23-22 08:00AM
Jan-17-22 09:40AM
07:40AM
Jan-14-22 06:27AM
Jan-04-22 08:30AM
Dec-13-21 08:30AM
Dec-08-21 08:30AM
Nov-16-21 08:30AM
Nov-08-21 08:30AM
Nov-02-21 08:30AM
Oct-25-21 09:00AM
Sep-24-21 07:25AM
Sep-22-21 12:27PM
08:30AM
Sep-15-21 04:01PM
Sep-08-21 08:44AM
Sep-02-21 03:31PM
Aug-18-21 11:54AM
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.